Treatment preferences among patients with mild-to-moderate atopic dermatitis

Abstract

Study purpose: New treatments for atopic dermatitis (AD) are emerging; however, little is known about the treatment preferences of patients with mild-to-moderate AD. To measure patients’ preferences, a cross-sectional, web-based discrete choice experiment (DCE) survey was developed and administered to 300 adults in the United States with a self-reported physician diagnosis of mild-to-moderate AD.

Materials and methods: In the DCE, respondents evaluated pairs of hypothetical AD treatment profiles defined by efficacy, risk, and mode and frequency of administration attributes. The DCE data were analyzed using a random parameters logit model. Subgroup analysis was used to investigate preference heterogeneity.

Results: The results revealed achieving clear or almost clear skin within 3-4 months of treatment was the most important attribute relative to all other study attributes. The results indicated that a topical cream applied twice daily was preferred to systemic treatments. Subgroup analysis revealed that respondents with lower self-assessed disease burden were more likely to choose topical over systemic treatments and less averse to the risk of pain, burning, and/or stinging from the medicine (all other treatment features remaining equal) than respondents with higher self-assessed disease burden.

Conclusion: The results of this study can help inform shared decision-making to manage mild-to-moderate AD.

Keywords:

• Discrete choice experiment
• atopic dermatitis
• patient preferences

Acknowledgements

The authors thank the individuals who participated in the study. Kimberly Moon of RTI Health Solutions provided overall project management for this study.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

Access to individual patient-level data is not available for this study. Information on Incyte’s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at: https://www.incyte.com/Portals/0/Assets/Compliance%20and%20Transparency/clinical-trial-data-sharing.pdf?ver=2020-05-21-132838-960

Additional information

Funding

This study was performed under a research contract between Incyte and RTI Health Solutions and was funded by Incyte. Shreekant Parasuraman is an employee of Incyte. Kelley Myers, Christine Poulos, and Anna Pierce are employees of RTI Health Solutions.